← All trials
NCT05504278
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 31, 2022
- Primary completion
- May 12, 2023
- Completion date
- Jul 31, 2027
- First posted
- Aug 17, 2022
- Last posted
- Aug 17, 2022
- Enrollment
- 144
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Innovent Biologics (Suzhou) Co. Ltd.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.